See more : Safa Systems & Technologies Li (SSTL.BO) Income Statement Analysis – Financial Results
Complete financial analysis of NanoVibronix, Inc. (NAOV) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of NanoVibronix, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- TAPARIA TOOLS LTD. (TAPARIA.BO) Income Statement Analysis – Financial Results
- NMDC Steel Limited (NSLNISP.BO) Income Statement Analysis – Financial Results
- Shagrir Group Vehicle Services Ltd (SRRPF) Income Statement Analysis – Financial Results
- Alumexx N.V. (ALX.AS) Income Statement Analysis – Financial Results
- Instone Real Estate Group SE (INS.DE) Income Statement Analysis – Financial Results
NanoVibronix, Inc. (NAOV)
About NanoVibronix, Inc.
NanoVibronix, Inc., through its subsidiary, NanoVibronix Ltd., focuses on the manufacture and sale of noninvasive biological response-activating devices that target biofilm prevention, wound healing, and pain therapy. Its principal products include UroShield, an ultrasound-based product to prevent bacterial colonization and biofilm in urinary catheters, enhance antibiotic efficacy, and decrease pain and discomfort associated with urinary catheter use; PainShield, a patch-based therapeutic ultrasound technology to treat pain, muscle spasm, and joint contractures; and WoundShield, a patch-based therapeutic ultrasound device, which facilitates tissue regeneration and wound healing. The company sells its products directly to patients, as well as through distributor agreements in the United States, Israel, Europe, India, and internationally. NanoVibronix, Inc. was incorporated in 2003 and is based in Elmsford, New York.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.28M | 752.00K | 1.70M | 623.00K | 530.00K | 318.00K | 239.00K | 229.00K | 147.00K | 203.00K | 211.00K | 166.00K | 94.00K |
| Cost of Revenue | 746.00K | 585.00K | 925.00K | 409.00K | 249.00K | 158.00K | 88.00K | 88.00K | 49.00K | 93.00K | 91.00K | 50.00K | 29.00K |
| Gross Profit | 1.54M | 167.00K | 770.00K | 214.00K | 281.00K | 160.00K | 151.00K | 141.00K | 98.00K | 110.00K | 120.00K | 116.00K | 65.00K |
| Gross Profit Ratio | 67.32% | 22.21% | 45.43% | 34.35% | 53.02% | 50.31% | 63.18% | 61.57% | 66.67% | 54.19% | 56.87% | 69.88% | 69.15% |
| Research & Development | 185.00K | 283.00K | 293.00K | 171.00K | 514.00K | 614.00K | 693.00K | 584.00K | 399.00K | 431.00K | 620.00K | 572.00K | 510.00K |
| General & Administrative | 3.92M | 3.93M | 5.06M | 3.77M | 3.82M | 2.64M | 2.08M | 1.36M | 747.00K | 589.00K | 366.00K | 128.00K | 87.00K |
| Selling & Marketing | 864.00K | 965.00K | 1.10M | 993.00K | 1.10M | 1.21M | 465.00K | 514.00K | 377.00K | 301.00K | 244.00K | 190.00K | 150.00K |
| SG&A | 4.79M | 4.90M | 6.16M | 4.76M | 4.92M | 3.85M | 2.55M | 1.87M | 1.12M | 890.00K | 610.00K | 318.00K | 237.00K |
| Other Expenses | 0.00 | 0.00 | -1.63M | 42.00K | -412.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 36.00K | 0.00 | 0.00 |
| Operating Expenses | 4.97M | 5.18M | 6.45M | 4.93M | 5.43M | 4.46M | 3.24M | 2.46M | 1.52M | 1.32M | 1.23M | 890.00K | 747.00K |
| Cost & Expenses | 5.72M | 5.76M | 7.38M | 5.34M | 5.68M | 4.62M | 3.33M | 2.55M | 1.57M | 1.41M | 1.32M | 940.00K | 776.00K |
| Interest Income | 0.00 | 54.00K | 48.00K | 147.00K | 15.00K | 0.00 | 0.00 | 0.00 | 0.00 | 8.00K | 0.00 | 1.00K | 1.00K |
| Interest Expense | 246.00K | 347.00K | 0.00 | 147.00K | 62.00K | 22.00K | 1.23M | 0.00 | 65.00K | 372.00K | 782.00K | 256.00K | 21.00K |
| Depreciation & Amortization | 1.00K | 1.00K | 2.00K | 2.00K | 4.00K | 6.00K | 5.00K | 7.00K | 9.00K | 9.00K | 10.00K | 9.00K | 10.00K |
| EBITDA | -3.44M | -5.01M | -14.25M | -4.16M | -5.75M | -4.28M | -3.64M | -2.69M | -2.38M | -1.33M | -1.23M | -1.01M | -692.00K |
| EBITDA Ratio | -150.46% | -673.54% | -433.98% | -757.14% | -1,048.87% | -1,344.34% | -1,313.39% | -1,014.85% | -1,238.10% | -1,024.14% | -771.56% | -608.43% | -736.17% |
| Operating Income | -3.44M | -5.01M | -5.68M | -4.72M | -5.15M | -4.30M | -3.09M | -2.32M | -1.42M | -1.21M | -1.11M | -774.00K | -682.00K |
| Operating Income Ratio | -150.50% | -666.49% | -335.28% | -757.46% | -971.89% | -1,353.14% | -1,293.31% | -1,011.35% | -968.71% | -596.55% | -526.07% | -466.27% | -725.53% |
| Total Other Income/Expenses | -246.00K | -401.00K | -8.57M | 408.00K | -660.00K | 22.00K | -1.84M | -398.00K | -1.43M | -1.39M | -844.00K | -501.00K | -41.00K |
| Income Before Tax | -3.68M | -5.41M | -14.25M | -4.31M | -5.81M | -4.28M | -4.93M | -2.71M | -2.86M | -2.60M | -1.95M | -1.28M | -723.00K |
| Income Before Tax Ratio | -161.28% | -719.81% | -840.71% | -691.97% | -1,096.42% | -1,346.23% | -2,061.51% | -1,185.15% | -1,942.86% | -1,279.80% | -926.07% | -768.07% | -769.15% |
| Income Tax Expense | 29.00K | 35.00K | 32.00K | 15.00K | -17.00K | -127.00K | 38.00K | 117.00K | 28.00K | 49.00K | 35.00K | 10.00K | -20.00K |
| Net Income | -3.71M | -5.45M | -14.28M | -4.33M | -5.79M | -4.15M | -4.97M | -2.83M | -2.88M | -2.65M | -1.99M | -1.28M | -723.00K |
| Net Income Ratio | -162.55% | -724.47% | -842.60% | -694.38% | -1,093.21% | -1,306.29% | -2,077.41% | -1,236.24% | -1,961.90% | -1,303.94% | -942.65% | -768.07% | -769.15% |
| EPS | -2.12 | -3.84 | -11.35 | -8.40 | -16.70 | -12.88 | -20.00 | -12.37 | -16.31 | -20.27 | -15.23 | -9.77 | -5.54 |
| EPS Diluted | -2.12 | -3.84 | -11.35 | -8.40 | -16.70 | -12.88 | -20.00 | -12.37 | -16.31 | -20.27 | -15.23 | -9.77 | -5.54 |
| Weighted Avg Shares Out | 1.75M | 1.42M | 1.26M | 514.91K | 346.97K | 322.42K | 248.20K | 228.92K | 176.82K | 130.57K | 130.57K | 130.57K | 130.57K |
| Weighted Avg Shares Out (Dil) | 1.75M | 1.42M | 1.26M | 514.91K | 346.97K | 322.42K | 248.20K | 228.92K | 176.82K | 130.57K | 130.57K | 130.57K | 130.57K |
NanoVibronix UroShield Approved for Sale through NHS Internal Supply Chain Contract
ELMSFORD, N.Y.--(BUSINESS WIRE)--NanoVibronix, Inc., (NASDAQ: NAOV), a medical device company utilizing the Company's proprietary and patented low intensity surface acoustic wave (SAW) technology, today announced its UroShield has been approved for sale by the U.K.'s National Health System's (NHS) internal...
NanoVibronix Sets Date for Annual Shareholder Meeting
ELMSFORD, N.Y.--(BUSINESS WIRE)--NanoVibronix, Inc., (NASDAQ: NAOV) (the “Company”), announced today that its annual meeting of shareholders (the “Annual Meeting”) will take place at 10 a.m. Eastern time on December 15, 2022. The Company will hold the Annual Meeting virtually via...
NanoVibronix Sets Date for Annual Shareholder Meeting
ELMSFORD, N.Y.--(BUSINESS WIRE)--NanoVibronix, Inc., (NASDAQ: NAOV) (the “Company”), announced today that its annual meeting of shareholders (the “Annual Meeting”) will take place at 10 a.m. Eastern time on December 15, 2022. The Company will hold the Annual Meeting virtually via...
NanoVibronix Announces Distribution of Series F Preferred Stock to Holders of its Common Stock
ELMSFORD, N.Y.--(BUSINESS WIRE)--NanoVibronix, Inc. (NASDAQ: NAOV) (“Nano” or the “Company”), a medical device company utilizing the Company's proprietary and patented low intensity surface acoustic wave (SAW) technology, today announced that its Board of Directors declared a dividend of one one-thousandth...
NanoVibronix Announces Distribution of Series F Preferred Stock to Holders of its Common Stock
ELMSFORD, N.Y.--(BUSINESS WIRE)--NanoVibronix, Inc. (NASDAQ: NAOV) (“Nano” or the “Company”), a medical device company utilizing the Company’s proprietary and patented low intensity surface acoustic wave (SAW) technology, today announced that its Board of Directors declared a dividend of one one-thousandth...
NanoVibronix Announces Receipt of Nasdaq Listing Determination; Company to Request Hearing
ELMSFORD, N.Y.--(BUSINESS WIRE)--NanoVibronix, Inc., (NASDAQ: NAOV), a medical device company utilizing the Company's proprietary and patented low intensity surface acoustic wave (SAW) technology, today announced that, on August 30, 2022, the Company received notice from the Nasdaq Listing Qualifications Staff...
NanoVibronix Announces Receipt of Nasdaq Listing Determination; Company to Request Hearing
ELMSFORD, N.Y.--(BUSINESS WIRE)--NanoVibronix, Inc., (NASDAQ: NAOV), a medical device company utilizing the Company's proprietary and patented low intensity surface acoustic wave (SAW) technology, today announced that, on August 30, 2022, the Company received notice from the Nasdaq Listing Qualifications Staff...
NanoVibronix Provides Business Update in Letter to Shareholders
ELMSFORD, N.Y.--(BUSINESS WIRE)--NanoVibronix, Inc., (NASDAQ: NAOV), a medical device company utilizing the Company's proprietary and patented low intensity surface acoustic wave (SAW) technology, today provided the following business update in a letter to shareholders from its Chief Executive Officer, Brian...
NanoVibronix Announces Webinar Series to Promote UroShield
ELMSFORD, N.Y.–(BUSINESS WIRE)–NanoVibronix, Inc., (NASDAQ: NAOV), a medical device company utilizing the Company’s proprietary and patented low inten...
NanoVibronix Announces Webinar Series to Promote UroShield
ELMSFORD, N.Y.--(BUSINESS WIRE)--NanoVibronix, Inc., (NASDAQ: NAOV), a medical device company utilizing the Company's proprietary and patented low intensity surface acoustic wave (SAW) technology, today announced its Australian distributor, DukeHill HC, is launching a series of educational webinars to present the...
Source: https://incomestatements.info
Category: Stock Reports